Clinical Trial Update: The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration. [Phase 3]

View source ↗

Summary

A Phase III trial evaluating rh-endostatin (Endostar) given as a continuous IV infusion plus GP chemotherapy versus GP chemotherapy alone in squamous cell lung …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• CISPLATIN (cisplatin)
• Endostar (recombinant human endostatin)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. | Conditions: Lung Cancer | Phase 3 | Status: UNKNOWN